Summary
To locate T cell determinants of glycoprotein D (gD) of herpes simplex virus type 1 (HSV-1), proliferation assays of lymphocytes obtained from 10 healthy HSV-seropositive individuals were performed using 34 overlapping gD peptides as antigens. Despite large differences between individual responses to the peptides both in number of stimulating peptides and gD regions, three regions (1–54, 110–214, and 290–314) induced a response in 50% or more of the HSV-seropositives. T cells were less frequently stimulated by peptides of region 210–294. No correlation was found between serological data and proliferative responses to the peptides. The diversity in T cell response to the peptides suggests a lack of immunodominance, implying that a single peptide/region of gD, or a combination of peptides, will not be sufficient to serve as a basis for a future HSV-1 vaccine.
This is a preview of subscription content, log in via an institution to check access.
References
Geerligs HJ, Feijlbrief M, Bolk M, Bos CA, Drijfhout JW, Welling GW, Welling-Wester S (1990) Reactivity of human sera with overlapping synthetic peptides of herpes simplex virus type 1 glycoprotein D. Arch Virol 114: 251–258
Geerligs HJ, Kocken CHM, Drijfhout JW, Weijer WJ, Bloemhoff W, Wilterdink JB, Welling GW, Welling-Wester S (1990) Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice. J Gen Virol 71: 1767–1774
Hall MJ, Katrak K (1986) The quest for a herpes simplex virus vaccine: background and recent developments. Vaccine 4: 138–150
Houghten A (1985) General method for the rapid solid phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 82: 5131–5135
Krishna S, Blacklaws BA, Overton HA, Bishop DHL, Nash AA (1989) Expression of glycoprotein D of herpes simplex virus type 1 in a recombinant baculovirus: protective responses and T cell recognition of the recombinant-infected cell extracts. J Gen Virol 70: 1805–1814
Long D, Madara TJ, Ponce de Leon M, Cohen GH, Montgomery PC, Eisenberg RJ (1984) Glycoprotein D protects mice against lethal challenge with herpes simplex virus type 1 and 2. Infect Immun 37: 761–764
Meignier B, Jourdier TM, Norrild B, Pereira L, Roizman B (1987) Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. J Infect Dis 155: 921–930
Rouse BT, Lopez C (1984) Strategies for immune intervention against herpes simplex virus. In: Rouse BT, Lopez C (eds) Immunobiology of herpes simplex virus infection. CRC Press, Boca Raton, pp 145–155
Stanberry LR, Bernstein LI, Burke RL, Pachl C, Myers MG (1987) Vaccination with recombinant herpesvirus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 155: 914–920
Watari E, Dietzschold B, Szokan G, Heber-Katz E (1987) A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2. J Exp Med 165: 459–470
Welling-Wester S, Scheffer AJ, Welling GW (1991) B and T cell epitopes of glycoprotein D of herpes simplex virus type 1. FEMS Microbiol Immunol 76: 59–68
Yamashita K, Heber-Katz E (1989) Lack of immunodominance in the T cell response to herpes simplex virus glycoprotein D after administration of infectious virus. J Exp Med 170: 997–1002
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Damhof, R.A., Drijfhout, J.W., Scheffer, A.J. et al. T cell responses to synthetic peptides of herpes simplex virus type 1 glycoprotein D in naturally infected individuals. Archives of Virology 130, 187–193 (1993). https://doi.org/10.1007/BF01319007
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01319007